HomeGRAL • NASDAQ
add
Grail Inc
Previous close
$80.69
Day range
$79.00 - $85.71
Year range
$13.52 - $103.00
Market cap
3.04B USD
Avg Volume
1.19M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 35.54M | 11.18% |
Operating expense | 146.55M | -37.88% |
Net income | -113.98M | 92.81% |
Net profit margin | -320.69 | 93.53% |
Earnings per share | -3.18 | — |
EBITDA | -91.68M | 49.34% |
Effective tax rate | 25.43% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 602.75M | -37.14% |
Total assets | 2.70B | -17.34% |
Total liabilities | 387.91M | -32.48% |
Total equity | 2.31B | — |
Shares outstanding | 36.05M | — |
Price to book | 1.26 | — |
Return on assets | -11.79% | — |
Return on capital | -13.48% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -113.98M | 92.81% |
Cash from operations | -76.96M | 55.20% |
Cash from investing | 70.37M | 5,177.13% |
Cash from financing | — | — |
Net change in cash | -6.47M | -100.85% |
Free cash flow | -29.88M | 75.95% |
About
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California founded in 2015 seeking to develop an early cancer screening test for people who do not have symptoms. As a startup it was a subsidiary of Illumina, which bought it outright in 2021.
In June 2021 Galleroi launched their liquid biopsy, or multi-cancer early detection test, which they called Galleri test. In 2023 EU regulators ordered Grail to be spun-out from Illumina which was completed on June 24, 2024. Wikipedia
Founded
2015
Headquarters
Website
Employees
1,000
